Recent Announcements

What’s New, Updates, and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the guidance.

In addition to updates to all the sections, the following new sections have been added to the guidance:

Read More

Glecaprevir/pibrentasvir and sofosbuvir/ velpatasvir/voxilaprevir have been approved by the FDA- update coming soon.

In addition to updates for all relevant sections in response to the new approvals, the following new sections will be released soon:

  • HCV in Children
  • HCV in Pregnancy
  • HCV Resistance Primer
     

FDA announcements:

Read More

What’s New and Updates/Changes

This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance. 

Read More

What’s New and Updates/Changes

The HCV Guidance Panel has reviewed new information that highlights the risk of HBV infection reactivation in patients who are coinfected and who clear HCV with DAAs. They have therefore chosen to alert providers. The updated information can be found in the Monitoring Patients Who Are Starting Hepatitis C Treatment, Are On Treatment, or Have Completed Therapy section of the Guidance.

Read More

What’s New and Updates/Changes

This version of the Guidance has been updated to reflect several important developments, including the recent approval of sofosbuvir/velpatasvir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

Read More

What’s New and Updates/Changes

This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

Read More

Guidance Sections Updated

In the Initial, Retreatment, and Monitoring sections, recommendations regarding the use of paritaprevir/ritonavir/ombitasvir plus dasabuvir in those with advanced liver disease have been revised based on an FDA warning issued on October 22, 2015.

Read More

Official Press Release - When and In Whom to Initiate HCV Therapy

View Official Press Release: When and In Whom to Initiate HCV Therapy Now Available at www.HCVguidelines.org

Read More

New Guidance Section

The following new section of the HCV Guidance has been released, Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens.

Read More

Guidance Sections Updated

The Initial, Retreatment, Monitoring, and Unique Populations (HIV/HCV Coinfection, Decompensated Cirrhosis, Post-Liver Transplantation, and Renal Impairment) sections have been revised based on newly available therapies and data.

Read More
Top